The deal comes one year after the drug from Gilead Sciences reached Europe.


According to reports the Ministry of Health and national drugs watchdog Infarmed managed to negotiated a price that will enable more patients to be treated for less than €25,000 per treatment.


Newspaper Público reports that the plan is to treat between 10,000 and 12,000 patients with the new drug over the next three years.